Goldman Sachs Reiterates Neutral on InterMune (ITMN)
ITMN has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity reiterated a “positive” rating on shares of InterMune in a research note to investors on Monday. Separately, analysts at Morgan Stanley (NYSE: MS) cut their price target on shares of InterMune from $17.00 to $15.00 in a research note to investors on Wednesday, May 9th.
InterMune opened at 10.24 on Tuesday. InterMune has a 1-year low of $9.67 and a 1-year high of $45.37. The company’s market cap is $669.6 million.
InterMune last released its earnings data on Thursday, April 26th. The company reported ($0.74) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.70) by $0.04. InterMune’s revenue was up 39.1% compared to the same quarter last year. Analysts expect that InterMune will post $-0.76 EPS next quarter.
InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.